New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension.
Pulmonary arterial hypertension
gene therapy
immunity
inflammation
initial combination therapy
macitentan
metabolism
pulmonary arterial denervation
riociguat
selexipag
serotonin.
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
10
2017
revised:
21
11
2017
accepted:
21
12
2017
pubmed:
10
2
2018
medline:
29
10
2019
entrez:
10
2
2018
Statut:
ppublish
Résumé
Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.
Identifiants
pubmed: 29421995
pii: CMC-EPUB-88322
doi: 10.2174/0929867325666180201095743
doi:
Substances chimiques
Endothelin Receptor Antagonists
0
Phosphodiesterase 5 Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2844-2864Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.